Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo

Elise Lavergne, Behazine Combadière, Olivia Bonduelle, Mutsunori Murahashi, Ji Liang Gao, Maud Maho, Alexandre Boissonnas, Philip M. Murphy, Patrice Debré, Christophe Combadière

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

CX3CR1 has been described previously as a marker of human cytotoxic effector cells We evaluated the possibility of using its ligand, CX3CL1, to redirect immune response against tumors When murine lymphoma cell lines (EL4 and its derivative EG7) stably transfected with human-CX3CL1 were injected s.c. into C57BL/6 mice, the tumor growth was severely impaired when compared with the growth of control cell lines This antitumor effect of CX3CL1 was also found in T- and B-cell-deficient Rag1-/- mice but vanished in natural killer (NK) cell-deficient beige mice and in CX3CR1-/- mice, suggesting the involvement of CX3CR1-expressing NK cells. In addition, increased NK cell infiltration was observed in CX3CL1-producing tumors compared with controls. The effect of CX3CR1 on tumor growth required host cytotoxic effector cell functions because both IFNγ-/- and perforin-/- mice were resistant to CX3CLI antitumor effect Finally, intratumoral injection of DNA plasmid coding for a chimeric immunoglobulin presenting the CX3CL1 chemokine domain provided strong antitumor activity. Together, these data demonstrate that the CX3CL1 can reduce incidence and size of lymphoma in vivo through increased recruitment of activated NK cytotoxic cells These findings offer the first evidence of the potential of chimeric immunoglobulin-chemokines in anticancer therapy.

Original languageEnglish
Pages (from-to)7468-7474
Number of pages7
JournalCancer Research
Volume63
Issue number21
Publication statusPublished - Nov 1 2003
Externally publishedYes

Fingerprint

Chemokine CX3CL1
Natural Killer Cells
Immunoglobulins
Lymphoma
Neoplasms
Growth
Cell Line
Inbred C57BL Mouse
Chemokines
Plasmids
B-Lymphocytes
Ligands
Injections
DNA
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lavergne, E., Combadière, B., Bonduelle, O., Murahashi, M., Gao, J. L., Maho, M., ... Combadière, C. (2003). Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo. Cancer Research, 63(21), 7468-7474.

Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo. / Lavergne, Elise; Combadière, Behazine; Bonduelle, Olivia; Murahashi, Mutsunori; Gao, Ji Liang; Maho, Maud; Boissonnas, Alexandre; Murphy, Philip M.; Debré, Patrice; Combadière, Christophe.

In: Cancer Research, Vol. 63, No. 21, 01.11.2003, p. 7468-7474.

Research output: Contribution to journalArticle

Lavergne, E, Combadière, B, Bonduelle, O, Murahashi, M, Gao, JL, Maho, M, Boissonnas, A, Murphy, PM, Debré, P & Combadière, C 2003, 'Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo', Cancer Research, vol. 63, no. 21, pp. 7468-7474.
Lavergne E, Combadière B, Bonduelle O, Murahashi M, Gao JL, Maho M et al. Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo. Cancer Research. 2003 Nov 1;63(21):7468-7474.
Lavergne, Elise ; Combadière, Behazine ; Bonduelle, Olivia ; Murahashi, Mutsunori ; Gao, Ji Liang ; Maho, Maud ; Boissonnas, Alexandre ; Murphy, Philip M. ; Debré, Patrice ; Combadière, Christophe. / Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo. In: Cancer Research. 2003 ; Vol. 63, No. 21. pp. 7468-7474.
@article{7ada92fe44da41f495dbd1e362557762,
title = "Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo",
abstract = "CX3CR1 has been described previously as a marker of human cytotoxic effector cells We evaluated the possibility of using its ligand, CX3CL1, to redirect immune response against tumors When murine lymphoma cell lines (EL4 and its derivative EG7) stably transfected with human-CX3CL1 were injected s.c. into C57BL/6 mice, the tumor growth was severely impaired when compared with the growth of control cell lines This antitumor effect of CX3CL1 was also found in T- and B-cell-deficient Rag1-/- mice but vanished in natural killer (NK) cell-deficient beige mice and in CX3CR1-/- mice, suggesting the involvement of CX3CR1-expressing NK cells. In addition, increased NK cell infiltration was observed in CX3CL1-producing tumors compared with controls. The effect of CX3CR1 on tumor growth required host cytotoxic effector cell functions because both IFNγ-/- and perforin-/- mice were resistant to CX3CLI antitumor effect Finally, intratumoral injection of DNA plasmid coding for a chimeric immunoglobulin presenting the CX3CL1 chemokine domain provided strong antitumor activity. Together, these data demonstrate that the CX3CL1 can reduce incidence and size of lymphoma in vivo through increased recruitment of activated NK cytotoxic cells These findings offer the first evidence of the potential of chimeric immunoglobulin-chemokines in anticancer therapy.",
author = "Elise Lavergne and Behazine Combadi{\`e}re and Olivia Bonduelle and Mutsunori Murahashi and Gao, {Ji Liang} and Maud Maho and Alexandre Boissonnas and Murphy, {Philip M.} and Patrice Debr{\'e} and Christophe Combadi{\`e}re",
year = "2003",
month = "11",
day = "1",
language = "English",
volume = "63",
pages = "7468--7474",
journal = "Cancer Research",
issn = "0008-5472",
number = "21",

}

TY - JOUR

T1 - Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo

AU - Lavergne, Elise

AU - Combadière, Behazine

AU - Bonduelle, Olivia

AU - Murahashi, Mutsunori

AU - Gao, Ji Liang

AU - Maho, Maud

AU - Boissonnas, Alexandre

AU - Murphy, Philip M.

AU - Debré, Patrice

AU - Combadière, Christophe

PY - 2003/11/1

Y1 - 2003/11/1

N2 - CX3CR1 has been described previously as a marker of human cytotoxic effector cells We evaluated the possibility of using its ligand, CX3CL1, to redirect immune response against tumors When murine lymphoma cell lines (EL4 and its derivative EG7) stably transfected with human-CX3CL1 were injected s.c. into C57BL/6 mice, the tumor growth was severely impaired when compared with the growth of control cell lines This antitumor effect of CX3CL1 was also found in T- and B-cell-deficient Rag1-/- mice but vanished in natural killer (NK) cell-deficient beige mice and in CX3CR1-/- mice, suggesting the involvement of CX3CR1-expressing NK cells. In addition, increased NK cell infiltration was observed in CX3CL1-producing tumors compared with controls. The effect of CX3CR1 on tumor growth required host cytotoxic effector cell functions because both IFNγ-/- and perforin-/- mice were resistant to CX3CLI antitumor effect Finally, intratumoral injection of DNA plasmid coding for a chimeric immunoglobulin presenting the CX3CL1 chemokine domain provided strong antitumor activity. Together, these data demonstrate that the CX3CL1 can reduce incidence and size of lymphoma in vivo through increased recruitment of activated NK cytotoxic cells These findings offer the first evidence of the potential of chimeric immunoglobulin-chemokines in anticancer therapy.

AB - CX3CR1 has been described previously as a marker of human cytotoxic effector cells We evaluated the possibility of using its ligand, CX3CL1, to redirect immune response against tumors When murine lymphoma cell lines (EL4 and its derivative EG7) stably transfected with human-CX3CL1 were injected s.c. into C57BL/6 mice, the tumor growth was severely impaired when compared with the growth of control cell lines This antitumor effect of CX3CL1 was also found in T- and B-cell-deficient Rag1-/- mice but vanished in natural killer (NK) cell-deficient beige mice and in CX3CR1-/- mice, suggesting the involvement of CX3CR1-expressing NK cells. In addition, increased NK cell infiltration was observed in CX3CL1-producing tumors compared with controls. The effect of CX3CR1 on tumor growth required host cytotoxic effector cell functions because both IFNγ-/- and perforin-/- mice were resistant to CX3CLI antitumor effect Finally, intratumoral injection of DNA plasmid coding for a chimeric immunoglobulin presenting the CX3CL1 chemokine domain provided strong antitumor activity. Together, these data demonstrate that the CX3CL1 can reduce incidence and size of lymphoma in vivo through increased recruitment of activated NK cytotoxic cells These findings offer the first evidence of the potential of chimeric immunoglobulin-chemokines in anticancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0242442490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242442490&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 7468

EP - 7474

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -